N-((3R,4R)-1-(2-(ethynylthio)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine

ID: ALA5266223

Chembl Id: CHEMBL5266223

Max Phase: Preclinical

Molecular Formula: C21H23N9S

Molecular Weight: 433.55

Associated Items:

Names and Identifiers

Canonical SMILES:  C#CSc1nc2nc(C)cc(N3CC[C@@H](C)[C@@H](N(C)c4ncnc5[nH]ccc45)C3)n2n1

Standard InChI:  InChI=1S/C21H23N9S/c1-5-31-21-26-20-25-14(3)10-17(30(20)27-21)29-9-7-13(2)16(11-29)28(4)19-15-6-8-22-18(15)23-12-24-19/h1,6,8,10,12-13,16H,7,9,11H2,2-4H3,(H,22,23,24)/t13-,16+/m1/s1

Standard InChI Key:  MUHLISKDYFWHPZ-CJNGLKHVSA-N

Alternative Forms

  1. Parent:

    ALA5266223

    ---

Associated Targets(Human)

MGC-803 (6426 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HGC-27 (1452 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
BGC-823 (3035 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
GES1 (603 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 433.55Molecular Weight (Monoisotopic): 433.1797AlogP: 2.74#Rotatable Bonds: 4
Polar Surface Area: 91.13Molecular Species: NEUTRALHBA: 9HBD: 1
#RO5 Violations: 0HBA (Lipinski): 9HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: 13.53CX Basic pKa: 6.44CX LogP: 4.21CX LogD: 4.17
Aromatic Rings: 4Heavy Atoms: 31QED Weighted: 0.39Np Likeness Score: -1.42

References

1. Shi XJ, Wang S, Li XJ, Yuan XH, Cao LJ, Yu B, Liu HM..  (2020)  Discovery of tofacitinib derivatives as orally active antitumor agents based on the scaffold hybridization strategy.,  203  [PMID:32682202] [10.1016/j.ejmech.2020.112601]

Source